• In late May 2026, the U.S. Supreme Court declined to hear the appeal in the long-running legal dispute between CareDx and Natera, effectively leaving the lower court’s ruling in place and closing this chapter of litigation.
• This resolution removes a major legal uncertainty for CareDx, clarifying its operating backdrop just as investors reassess the company’s business outlook and risk profile.
• Next, we’ll explore how the Supreme Court’s rejection of the appeal could reshape CareDx’s investment narrative and perceived risk profile.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

CareDx Investment Narrative Recap

To own CareDx, you need to believe its transplant diagnostics and expanding test menu can support sustainable demand despite shifting reimbursement and regulatory pressures. The Supreme Court’s decision to leave the Natera ruling intact removes a legal overhang, but does not directly change the key near term swing factors, which remain Medicare policy decisions and reimbursement levels for core tests, as well as execution through the ongoing CFO transition and operational upgrades.

The most relevant recent development alongside the litigation resolution is CareDx’s raised full year 2026 revenue guidance to US$420–US$444 million, which already factors in an estimated six month Medicare LCD impact of about US$7.5 million. With the court case closed and updated guidance on the table, investor attention is likely to focus even more on how future LCD implementation, payer behavior and product mix could influence whether CareDx can stay within or above that guided range.

Yet against this clearer legal backdrop, investors should be aware of the lingering risk that future Medicare reimbursement changes could still...

CareDx's narrative projects $524.6 million revenue and $49.9 million earnings by 2029. This requires 8.3% yearly revenue growth and a $58.1 million earnings increase from -$8.2 million today.

Uncover how CareDx's forecasts yield a $25.80 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Before this ruling, the most optimistic analysts were modeling about US$505.4 million of revenue and US$8.9 million of earnings by 2028, which is far more upbeat than the reimbursement risk narrative you just read, and you should consider how this legal outcome might shift both views over time.

Explore 3 other fair value estimates on CareDx - why the stock might be worth just $25.80!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CareDx research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CareDx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CareDx's overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.